SynthesisFrontiers in medicine2026
Efficacy of mizoribine in renal transplant recipients on calcineurin inhibitor-based immunosuppression: a network meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the efficacy of mizoribine (MZR) in renal transplant recipients on a calcineurin inhibitor (CNI)-based maintenance regimen and to compare it with other immunosuppressants [mycophenolic acid (MPA), mycophenolate mofetil (MMF), cyclophosphamide (CTX)] utilizing network meta-analysis (NMA). Materials and methods: Randomized controlled trials (RCTs) of MZR and other immunosuppressants in renal transplant recipients were retrieved from databases including PubMed, Web of Science, and Science Direct. Study quality was assessed. NMA was performed utilizing Results: A total of 11 studies were included. Within CNI-based maintenance regimens, MZR showed no significant differences compared to MPA, MMF, or CTX in terms of patient survival (3-year) or graft survival ( Conclusion: In CNI-based maintenance therapy for renal transplant recipients, MZR is equivalent to MPA and MMF in ensuring long-term patient and graft survival. It exhibits a distinct safety profile: significantly superior gastrointestinal tolerability and a lower risk of leukopenia, albeit with a potentially higher risk of BK viremia. In terms of renal function, MZR demonstrates an intermediate effect, superior to MMF but inferior to CTX. Clinical selection should involve weighing the risks of infection (particularly BK virus) against gastrointestinal tolerability based on individual patient characteristics. MZR represents an effective and well-tolerated important alternative to traditional MMF/MPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.